



**E Journal  
of Cardiovascular  
Medicine**

| Volume **3** | Issue **2** |

| July-December **2015** |

[www.ejcvsmmed.org](http://www.ejcvsmmed.org)

# E Journal of Cardiovascular Medicine

**Endovascular (non-operative) abdominal  
aortic aneurysm treatment: Where are we?**

*Ali Gürbüz*

**Life saving collaterals: Right-to-left and left-to-right**

*Umut Kocabaş, Ferhat Özyurtlu, Bahadır Çöllü*

**Left ventricular myxoma**

*Ali Kutsal, Murat Koç*

**Alternative intervention for pericardial  
effusion article type: Case report**

*Mehmet Atay, Onur Saydam, Vedat Bakuy, Alparslan Şahin*

E-Journal of Cardiovascular Medicine welcomes scientific contributions in the field of cardiovascular and thoracic surgery - all aspects of surgery of the heart, vessels and the chest in various article types: new ideas, brief communications, work in progress, follow-up studies, original articles, best evidence topics, case reports, reports on unexpected results etc. All manuscripts shall be reviewed by the Editor-in-Chief, Associate Editors, Invited Referees and a Statistician when appropriate. If accepted, articles will be posted online and opened up for discussion. Acceptance criteria are based on the originality, significance, and validity of the material presented.

All material to be considered for publication in E-Journal of Cardiovascular Medicine should be submitted in electronic form via the journal's online submission system. (<http://my.ejmanager.com/ejcm/>)

A cover letter should be enclosed to all new manuscripts (to be filled in online), specifying the name of the journal and the type of paper, and including the following statements:

- The manuscript should not be previously published in print or electronic form and is not under consideration by another publication.
- All authors should contribute to the content of the article.
- All authors should read and approve the submission of the manuscript to ICVTS.
- Subject to acceptance, authors will sign an exclusive license to publish.
- No ethical problem or conflict of interest should exist.

If your first language is not English, we recommend that you consult an English language editing service to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication.

Manuscripts should be prepared using a word-processing package (save in .doc, .docx or .rtf format). The font type and font size should preferably be Arial or Times New Roman 11 points. The manuscript should be double-spaced and should include line and page numbers. The lines of the reference list do not need to be numbered; include a section break before.

### Manuscripts should be organized as follows:

(a) Title page; (b) Abstract and Key words; (c) Text with the following sections (not applicable for article types with unstructured abstracts): Introduction, Materials and Methods, Results, Discussion, Acknowledgement (optional), Funding statement, Conflict of interest statement, (d) Figure (and Video) legends; (e) Tables; (f) References.

**Title page (1st page):** Title: should be brief and descriptive (100 characters) - no abbreviations are allowed, even if well known.

**Authors:** list all authors by full first name, initial of or full middle name and family name. Qualifications are not required. Ensure the author names correspond (in spelling and order of appearance) with the metadata of the system

**Institution(s):** include the name of all institutions with the location

(department, institution, city, country) to which the work should be attributed (in English). Use superscript numbers to connect authors and their department or institution.

**Corresponding author:** The full name, full postal address, telephone/fax numbers and the e-mail address should be typed at the bottom of the title page.

**Meeting presentation:** If the manuscript was (or will be) presented at a meeting, include the meeting name, venue, and the date on which it was (or will be) read; also indicate if you have submitted an Abstract of this manuscript for the EACTS or ESTS annual meeting and whether it has been accepted (if known).

**Word count:** The total number of words of the whole article (including title page, abstract, main text, legends, tables and references) must be specified on the title page.

**Abstract (2nd page):** An abstract should be a concise summary of the manuscript. Reference citations are not allowed. The abstract should be factual and free of abbreviations, except for SI units of measurement.

**Keywords:** Following the abstract, 3-6 keywords should be given for subject indexing.

**Introduction:** Should state the purpose of the investigation and give a short review of pertinent literature.

**Materials and methods:** Should be described in detail with appropriate information about patients or experimental animals. Use of abbreviations renders the text difficult to read; abbreviations should be limited to SI units of measurement and to those most commonly used, e.g. VSD, ASD, CABG (abbreviations should not be included in headings and extensions should be included at first mention).

**Results:** Results should be reported concisely and regarded as an important part of the manuscript. They should be presented either in tables and figures, and briefly commented on in the text, or in the text alone. Repetition of results should be avoided!

**Discussion:** The discussion is an interpretation of the results and their significance with reference to pertinent work by other authors. It should be clear and concise.

**Acknowledgement:** Acknowledgements and details of non-financial support must be included at the end of the text before the references. Personal acknowledgements should precede those of institutions or agencies.

**Tables:** All tables must be included in the manuscript file, should start on separate pages and be accompanied by a title, and footnotes where necessary. The tables should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in parentheses at the top of each column and not repeated in each line of the table.

**References:** Authors are responsible for checking the accuracy of all references. If you use EndNote or Reference Manager to facilitate referencing citations (not required for submission), this journal's style is available for use. References should be numbered in order of appearance in the text (in Arabic numerals in parentheses) and must be listed numerically in the reference list. Journal titles and author initials should be properly abbreviated and punctuated.

## Editor-in-Chief

### Prof. Öztekin Oto

*FESC, FACC / President, Heart and Health Foundation of Turkey / Izmir / Turkey*

## Asistant Editors

### Prof. Ali Kutsal

*Sami Ulus Children Hospital Department of  
Cardiovascular Sugery / Ankara / Turkey*

### Prof. Erdem Silistreli

*Dokuz Eylül University, Department of Cardiovascular  
Sugery / Izmir / Turkey*

### Prof. Bektaş Battaloğlu

*İnönü University, Department of Cardiovascular Sugery  
Malatya / Turkey*

### Dr. Onur Saydam

*Karaman State Hospital Cardiovascular Surgery  
Karaman / Turkey*

### Dr. Emre Doğan

*Trabzon Ahi Evren Cardiovascular Surgery Hospital  
Trabzon / Turkey*

### Dr. Taylan Adademir

*Kartal Koşuyolu Resarch Hospital / Istanbul / Turkey*

## Owner

© TÜSAV Heart and Health Foundation of Turkey

## Administration Office

Şair Eşref Bulvarı, 1402 Sk. No. 2/2 Özbaş Apt.  
Alsancak - Izmir / Turkey  
Tel: + 90 232 464 19 63 / Fax: +90 232 464 24 70  
e-mail: info@oztekinoto.com | info@tksv.org

## Publishing Coordinator

### Hüseyin Kandemir

huseyin@medikalakademi.com.tr  
Medikal Akademi Yayıncılık ve Prodüksiyon Tic. Ltd. Sti.  
Halaskargazi Cad. No: 172, D: 134 - Şişli / İstanbul  
Tel: +90 537 309 29 55, Faks: (0212) 233 90 61  
www.medikalakademi.com.tr/hizmetlerimiz

## International Scientific Advisory Board

### Prof. Harald Kaemmerer

*German Heart Centre / Munich / Germany*

### Prof. Marko Turina

*University Hospital of Zurich / Zurich / Switzerland*

### Prof. Frank W. Selke

*Chief of Cardiothoracic Surgery at Brown Medical School  
Rhode Island / USA*

### Prof. Joseph E. Bavaria

*Hospital of the University of Pennsylvania  
Philadelphia / USA*

### Prof. Fausto Pinto

*Director of Lisbon Cardiovascular Institute / Portugal  
& President of the European Society of Cardiology*

### Prof. Lazar Davidovic

*Belgrade Medical School Cardiovascular Surgery  
Belgrade / Serbia*

### Prof. Stephan Schueler

*Tyne Freeman Hospital, Department for Cardiothoracic  
Surgery Newcastle / United Kingdom*

### Prof. Piotr Kasprzak

*University Hospital Regensburg, Director of Vascular  
Surgery / Regensburg / Germany*

### Prof. Jose Luis Pomar

*Hospital Clinico de Barcelona, Department of  
Cardiovascular Sugery / Barcelona / Spain*

**Assoc. Prof. Hakan Aydın**

*Sami Ulus in Ankara Training and Research Hospital,  
Cardiovascular Surgery / Ankara / Turkey*

**Assoc. Prof. Barış Akça**

*Department of Cardiovascular Surgery, Inonu University  
School of Medicine / Malatya / Turkey*

**Dr. Rezan Aksoy**

*Siyami Ersek Training and Research Hospital,  
Cardiovascular Surgery / Istanbul / Turkey*

**Dr. Şafak Alpat**

*Birmingham Children's Hospital Pediatric Cardiovascular  
Surgery / Birmingham / UK*

**Dr. Mustafa Aldemir**

*Kocatepe University, Department of Cardiovascular  
Surgery / Afyon / Turkey*

**Dr. Mehmet Atay**

*Bakırköy Sadi Konuk Research Hospital, Cardiovascular  
Surgery / Istanbul / Turkey*

**Assoc. Prof. Vedat Bakuy**

*Bakırköy Sadi Konuk Education and Research Hospital,  
Cardiovascular Surgery / Istanbul / Turkey*

**Dr. Deniz Cevirme**

*Kartal Koşuyolu Yüksek İhtisas Research and Education  
Hospital / Istanbul / Turkey*

**Prof. Ferit Çiçekcioğlu**

*Bozok University, Training and Research Hospital,  
Cardiovascular Sugery / Yozgat / Turkey*

**Assoc. Prof. Ertan Demirdaş**

*Bozok University Research and Application Hospital and  
Cardiovascular Surgery / Yozgat / Turkey*

**Assoc. Prof. Yüksel Dereli**

*Necmettin Erbakan University, Meram Midical Faculty  
Hospital, Cardiovascular Surgery / Konya / Turkey*

**Dr. Vehbi Doğan**

*Sami Ulus Training and Research Hospital, Pediatric  
Cardiology / Ankaral / Turkey*

**Dr. Çağrı Düzyol**

*Kocaeli Derince Education and Research Hospital  
Cardiovascular Surgery / Kocaeli / Turkey*

**Assoc. Prof. Hüseyin Ede**

*Bozok University Research and Application Hospital  
Cardiology / Yozgat / Turkey*

**Dr. İlker Ertuğrul**

*Sami Ulus Training and Research Hospital, Pediatric  
Cardiology / Ankaral / Turkey*

**Prof. Niyazi Görmüş**

*Necmettin Erbakan University, Meram Midical Faculty  
Hospital, Cardiovascular Surgery / Konya / Turkey*

**Assoc. Prof. Mustafa Gülgün**

*GATA Department of Pediatrics, Division of Pediatric  
Cardiology / Ankara / Turkey*

**Dr. Mehmet Kalender**

*Derince Training and Research Hospital, Cardiovascular  
Surgery / Kocaeli / Turkey*

**Assoc. Prof. Osman Kayapınar**

*Duzce University, Midical Faculty Department of  
Cardiology / Düzce / Turkey*

**Assoc. Prof. Ulaş Kumbasar**

*Hacettepe University Medical School Cardiovascular  
Surgery / Ankaral / Turkey*

**Dr. José Luis Serrano Martínez**

*University Hospital of Granada, Department of Internal  
Medicine / Granada / Spain*

**Dr. Vinod Namana**

*Maimonides Medical Center, Department of Medical  
Research / New York / USA*

**Dr. Silvio Nocco**

*Sirai Hospital, Department of Cardiology  
Carbonia / Italy*

**Dr. Akihiko Ikeda**

*Tsukuba Medical Center Hospital, Cardiovascular  
Surgery / Tsukuba / Japan*

**Dr. Richard W Issitt**

*Great Ormond Street Hospital, Cardiac Surgery -  
Pediatric Cardiology / London / UK*

**Prof. Murat Özeren**

*Mersin University Medical School, Cardiovascular  
Surgery / Mersin / Turkey*

**Dr. Tanıl Özer**

*Kartal Koşuyolu Yüksek İhtisas Research and Education  
Hospital / Istanbul / Turkey*

**Dr. Gökhan Sargin**

*Adnan Menderes University Medical School,  
CInternal Medicine / Aydın / Turkey*

**Dr. Stefano Salizzoni**

*Città della Salute e della Scienza, Cardiac Surgery,  
Cardiac Surgery / Turin / Italy*

**Dr. Mustafa Seren**

*Ankara 29 Mayıs State Hospital and Cardiovascular  
Surgery / Ankaral / Turkey*

**Assoc. Prof. Ömer Tanyeli**

*Necmettin Erbakan University, Meram Midical Faculty  
Hospital, Cardiovascular Surgery / Konya / Turkey*

**Dr. Mustafa Yılmaz**

*Sami Ulus Training and Research Hospital, Pediatric  
Cardiology / Ankaral / Turkey*

| Volume **3** | Number **2** | July-December **2015** |

## Review

**Endovascular (non-operative) abdominal  
aortic aneurysm treatment: Where are we? | 19**

Ali Gürbüz

## Case Report

**Life saving collaterals: Right-to-left and left-to-right | 24**

Umut Kocabaş, Ferhat Özyurtlu, Bahadır Çöllü

**Left ventricular myxoma | 27**

Ali Kutsal, Murat Koç

**Alternative intervention for pericardial effusion article type: Case report | 31**

Mehmet Atay, Onur Saydam, Vedat Bakuy, Alparslan Şahin

**Heart sarcoma and invasion of the mitral valve: Case report | 35**

Lakehal Redha, Aimer Farid, Bouharagua Rabeh, Cherif Samiha, Massikh Nadjet,

Aziza Baya, Bendjaballah Soumaya, Boukharoucha Radouane, Brahami Abdelmallek

# Endovascular (non-operative) abdominal aortic aneurysm treatment: Where are we?

Ali Gürbüz<sup>1</sup>

<sup>1</sup> İzmir Atatürk Training and Research Hospital Cardiovascular Surgery Clinic, Prof. MD, İzmir / Turkey

## Abstract

Though the long-term mortality and morbidity results of patients who underwent endovascular treatment modalities are unknown, we recommend endovascular treatment to be administered in patients with high risk for open surgery and in centers with proper hybrid operating room conditions. In view of the tendency for less invasive methods for the treatment option in recent years, cardiovascular surgeons should review their positions on this. Assuming the 52% of the vascular interventions in 2012 will be performed via endovascular routes, the importance of this will be understood again. Cardiovascular surgery specialists are at a crossroads.

**Keywords:** Aortic aneurysm, aneurysm diameter, endovascular treatment

Gurbuz A. Endovascular (Non-operative) abdominal aortic aneurysm treatment: Where are we?  
EJCM 2015; 03 (2): 19-23. Doi: 10.15511/ejcm.15.00219.

Aortic aneurysm is a condition in which the normal diameter in a localized site expands more than 50% (1.5 fold). Normal infrarenal aorta diameter is 21.4 mm in males and 18.7 mm in females. Abdominal aortic aneurysm (AAA) can be explained as the diameter of infrarenal aorta at a localized site permanently exceeding 3 cm. It is seen 5% of males over 50 years. This rate increases with the increasing average age and advancements in diagnostic modalities.<sup>(1)</sup> AAA generally shows 0.5 cm expansion per year, and rupture develops as a result of its natural progress. Until rupture stage, mostly, asymptomatic course is observed. The risk of rupture is proportional to the diameter, and is increased in aneurysms over 5.5 cm. The cases should be treated under elective condition before rupture development.<sup>(1,2,3)</sup>

## Clinical Presentation

Approximately 75% of the cases have asymptomatic course. Symptoms are usually manifested with the growth of aneurysm sack, and rupture, embolization and thrombosis as a result of the pressure of this growth to surrounding tissues.<sup>(2)</sup>

### Clinical symptoms can be examined in three groups:

1- Asymptomatic period: Includes approximately 75% of AAAs, and is detected by routine examination or testing.

2- Symptomatic period: The most common symptom is abdominal and low-back pain. Abdominal pain may be continuous or intermittent, mild or severe. As a result of the pressure of aneurysm sack, nausea, vomiting, dyspepsia may occur. It may manifest itself with extremity ischemia due to distal embolization or aneurysm thrombosis.

3- Rupture Period: Severe abdominal and low back pain that has sudden onset and do not change with position indicates rapid growth or rupture. Approximately 20% of the cases in our country admits to hospital with rupture. Rupture patients are in shock, cold, sweaty and hypotensive.<sup>(2,4)</sup>

## Diagnosis

Detection of aneurysms over 3.5 cm with physical examination is actually 15%.<sup>5</sup> Currently, ultrasonography (USG) remains to be valuable for the initial diagnosis. Also, Contrast-enhanced Computerized Tomography (CT) which is a successful, relatively cheap, fast, and a reliable diagnostic modality in showing the rupture and aneurysm extension is a good option especially in patients who will undergo surgery. Contrast-enhanced CT should include thoracoabdominal sections. This way, accompanying thoracic aneurysms can also be detected. Angiography should be preferred generally in cases with accompanying peripheral arterial disease, renal artery stenosis or fistulization suspicion.

While mortality (30-day) in elective surgery cases is approximately 5%, it is around 50% in rupture patients. As this rate only includes the patients who reach the hospital, the real mortality rate of ruptured abdominal aneurysms is around 90%. Due to high mortality of the rupture, early diagnosis and elective treatment show the importance USG screening especially in patients over 60-65 years with AAA-related risk factors.

### AAA related risk factors:

- Smoking
- Family history
- Hypertension
- COPD (Chronic obstructive pulmonary disease)
- Atherosclerotic disease (carotid stenosis, peripheral artery disease, etc.)
- Peripheral artery aneurysm (especially popliteal and iliac artery)

## Treatment

Aneurysm diameter has a great importance in the treatment of AAAs. The risk of rupture development under 5 cm is reported to be 5%.<sup>(6)</sup> Annual risk of rupture that is increased proportionally with aneurysm diameter has been stated to be 0% for <4 cm, 1% for 4.5 cm, 11% for 5.5 cm and 26% for 6.5 cm. As is seen, there is a logarithmic relation between diameter increase and the risk of rupture. Many surgeons believe

that surgery should be preferred in conditions in which the risk of rupture is more than the operative risk. One group advocates early surgical intervention (under 5 cm) and states that operative mortality is very low in young cases with low risk of surgery, that comorbidity and surgical risk may increase with the advancing age, and that for these reasons early surgical intervention is a good option.

In AAA with the diameter of 3-5 cm, in patients with no or less than 0.5 cm annual aneurysm diameter increase, follow-up is recommended.

- Patients whom recommended operative treatment (Surgery indications)
- Patients with an active live and AAA diameter of 5.5-5.9 cm
- All patients with the diameter of 6 cm and over
- Symptomatic patients with rapid diameter increase (>0.5cm in 6 months)
- There are two strategies as surgical treatment methods.
  - Open surgery
  - Endovascular surgery (EVAR)
- While 30-day mortality of open surgery technique in elective AAA repair in 5%, and it has

15-30% rate of major complications.<sup>(7)</sup> Operative mortality may reach upto 50% in high risk patients.<sup>(8)</sup> Foreseeable major risks during classic surgical intervention are perioperative cardiac injury, and respiratory and renal failure.

At the present day, in addition to AAA screening, another factor that may reduce mortality rate and is a new treatment modality is endovascular aneurysm repair (EVAR) which is becoming widespread with fields of indication increasing day by day.

EVAR is applied since 1990s. In our country and our clinic, it became available in 2000s. It is a minimal invasive method as the physiological stress in the body and mortality rate is 3-fold less than open surgery, it is associated less morbidity and shorter anesthesia and intensive care period.<sup>9</sup> The efficacy of this method is

still being investigated in clinical trials, and the trials in which the early- and medium-term results can be assessed were conducted (UK-EVAR, DREAM, EUROSTAR). Long-term results remain to be unknown.<sup>(10,11,12,13,14,15)</sup>

**Eligibility for EVAR Treatment:** In order for AAA cases to be eligible for endovascular procedure, they need to have vascular anatomic properties. Contrast-enhance multislice CT and angiographic imaging are used for this. **According to this:**

- Aneurysm neck length should be > 15mm
- Diameter of the neck should be < 30 mm
- Neck angle should be > 60°
- Mural thrombus in the neck should be < 2 mm
- The diameter of external iliac artery should be > 7 mm
- Iliac angle should be > 90°
- Terminal aorta (Common iliac artery bifurcation) should be > 20 mm.

**Grafts used in EVAR Treatment:** As the initial grafts had aorto-aortic tubular structure, there was a high rate of early complications. At the present day usually, branched (aorto-biiliac) or straight aortoiliac (aorto-uniiliac) grafts with stent are used. When uniiliac grafts are used, the contralateral iliac artery is occluded, thereby femoro-femoral bypass is performed. With the development of fenestrated stent grafts, stent extension at suprarenal level is also possible. Thus, it facilitates the treatment AAA with short proximal neck or extending to suprarenal level.

Endovascular AAA repair can be applied under local, regional or general anesthesia. It is a technique which does not require major abdominal surgery. With this aspect, it is preferable in high-risk (serious cardiopulmonary disease or advanced age, accompanied morbid obesity and previous abdominal surgery) cases. However, after its feasibility is understood, it was started to be used in many patients with moderate and low risk patients with anatomical suitability. Its area of use gradually increases.<sup>16</sup> However, there are problematic conditions associated with this treatment modality in-

cluding anatomical nonconformity, endoleak, graft occlusion, aortic balloon dilatation.

### The advantages of Endovascular Treatment Modality in AAA

- Short period of procedure
- No cross-clamp use
- Less organ injury
- Less loss of blood, hence less blood transfusion
- Oral feeding within a short span of time
- Short duration of hospitalization

Due to great advancements in technology within the last 10 years, the tendency to EVAR as treatment modality in AAA cases has increased. In the upcoming years with more advanced devices, approximately 90% of AAA is thought to be treated with this method.<sup>(9)</sup>


In Izmir Ataturk Training and Research Hospital Cardiovascular Surgery Clinic, EVAR administration in AAA was started in 2003, and successfully applied to 68 patients with infrarenal AAA until the end of 2008. In our clinic, one of the pioneers of EVAR in

the world and Turkey, open surgery treatment of AAA gradually decreases and EVAR treatment is increasing. (Figure 1)

Though the long-term mortality and morbidity results of patients who underwent endovascular treatment modalities are unknown, we recommend endovascular treatment to be administered in patients with high risk for open surgery and in centers with proper hybrid operating room conditions.

In view of the tendency for less invasive methods for the treatment option in recent years, cardiovascular surgeons should review their positions on this. Assuming the 52% of the vascular interventions in 2012 will be performed via endovascular routes, the importance of this will be understood again. Cardiovascular surgery specialists are at a crossroads.

Also, new regulations should be made with rapid review of training programs of Cardiovascular surgery. Our centers should understand the importance of hybrid operation room, and make efforts to establish them.



## References

1. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, Thompson SG, Walker NM; Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet*. 2002 Nov 16;360(9345):1531-9.
2. Türk Kalp Damar Cerrahisi Derneği Aort Cerrahisinde Tanı ve Tedavi Kılavuzu-2008 :36-56;86-96.
3. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, Ballard DJ, Messina LM, Gordon IL, Chute EP, Krupski WC, Bussittil SJ, Barone GW, Sparks S, Graham LM, Rapp JH, Makaroun MS, Moneta GL, Cambria RA, Makhoul RG, Eton D, Ansel HJ, Freischlag JA, Bandyk D; Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med*. 2002 May 9;346(19):1437-44.
4. Kalp ve Damar Cerrahisi. Enver Duran. *Cilt I*;725-741
5. Bede SD, Ballard DJ, James EM, ve ark. Positive predictive value of clinical suspicion of abdominal aortic aneurysm: Implications for efficient use of abdominal Ultrasonography. *Arch Intern Med*. 1990;150;549
6. Sterpetti AV, Cavallaro A, Cavallari N, Allegrucci P, Tamburelli A, Agosta F, Bartoli S. Factors influencing the rupture of abdominal aortic aneurysms. *Surg Gynecol Obstet*. 1991 Sep;173(3):175-8.
7. Blankensteijn JD, Lindenburg FP, Van der Graaf Y, Eikelboom BC. Influence of study design on reported mortality and morbidity rates after abdominal aortic aneurysm repair *Br J Surg*. 1998 Dec;85(12):1624-30.
8. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variables predicting morbidity and mortality *J Vasc Surg*. 1989 Mar;9(3):437-47
9. Muhammad S. Sajid, Mittal Desai, Zishan Haider, Daryll M. Baker and George Hamilton, Department of Vascular Surgery, Royal Free Hospital, Hampstead, London, UK Endovascular Aortic Aneurysm Repair (EVAR) Has Significantly Lower Perioperative Mortality in Comparison to Open Repair: A Systematic Review *Asian Journal of Surgery* Vol 31:2008
10. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair *Br J Surg*. 2002 Jun;89(6):714-30. Review.
11. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG; EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial *Lancet*. 2004 Sep 4-10;364(9437):843-8
12. Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, Buskens E, Grobbee DE, Blankensteijn JD; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms *N Engl J Med*. 2004 Oct 14;351(16):1607-18
13. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. *Lancet*. 2005 Jun 25-Jul 1;365(9478):2179-86
14. Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM, Verhagen HJ, Buskens E, Grobbee DE; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms *N Engl J Med*. 2005 Jun 9;352(23):2398-405
15. Harris PL, Buth J. An update on the important findings from the EUROSTAR EVAR registry *Vascular*. 2004 Jan;12(1):33-8
16. Anderson PL, Arons RR, Moskowitz AJ, Gelijns A, Magnell C, Faries PL, Clair D, Nowygrod R, Kent KC. A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results *J Vasc Surg*. 2004 Jan;39(1):10-9

Received: 23/11/2014

Accepted: 04/03/2015

Published: 15/10/2015

### Disclosure and conflicts of interest:

Conflicts of interest were not reported.

### Corresponding author:

Prof. Dr. Ali Gürbüz

**Mail:** ali.gurbuz@ikc.edu.tr

# Life saving collaterals: Right-to-left and left-to-right

Umut Kocabaş<sup>1</sup>, Ferhat Özyurtlu<sup>2</sup>, Bahadır Çöllü<sup>2</sup>

<sup>1</sup>) Department of Cardiology, Soma State Hospital, Manisa, Turkey

<sup>2</sup>) Department of Cardiology, Grandmedical Hospital, Manisa, Turkey

## Abstract

Coronary collaterals are anastomotic connections between portions of the coronary arteries. The coronary collateral circulation as an alternative source of blood supply has shown benefits such as limited infarct size, left ventricular remodelling and preserved left ventricular systolic functions.

**Keywords:** Coronary artery disease, collateral circulation, prevention.

*Kocabaş U., Özyurtlu F. and Çöllü B. Life saving collaterals: Right-to-left and left-to-right  
EJCM 2015; 03 (2): 24-26. Doi: 10.15511/ejcm.15.00224.*

*Copyright © 2015 Heart and Health Foundation of Turkey (TÜSAV). Published by Medikal Akademi.  
This article is licensed by Medikal Akademi and TÜSAV under the terms of Creative Commons Attribution License.*

## Case


A 48 year-old male patient referred to cardiology clinic with typical anginal symptoms. There was not any remarkable disease in the patient's previous medical history. The 12-lead electrocardiogram showed ischemic changes. Transthoracic echocardiography showed mild hypokinesia in inferior wall, left ventricular ejection fraction was preserved and calculated 50% with Simpson method. Coronary angiography revealed chronic total occlusion of right coronary artery (RCA) and left-anterior descending (LAD) artery both. Interestingly, coronary collaterals originate from proximal part of RCA were retrogradely filling the total occluded LAD and supplies enough flow to the LAD area at risk for infarction (**Panel A, black arrows and asterisk**). Following retrograde filling of LAD, septal collaterals which originated from the retrogradely filled LAD were seen to fill distal RCA retrogradely again and supplies enough flow to the RCA area at risk for infarction (**Panel B-D, black arrows**). Those united collaterals were suc-

cessful at providing the blood supply, although with the chronic total occlusion of both RCA and LAD, a large area of myocardial ischemia was under at risk. The patient underwent coronary artery bypass graft surgery.

## Discussion

Patients with coronary artery disease, coronary collateral circulation is associated with a reduction in infarct size, left ventricular dysfunction and cardiovascular events, which translates into a relevant improvement in survival.<sup>(1)</sup> Well-developed coronary collaterals may help protect the myocardium from infarction during episodes of ischemia and may extend the limited number of valuable "golden hours" from the onset of an acute myocardial infarct to successful coronary reperfusion.<sup>(2)</sup>

In our case, myocardial salvage by extent collateral circulation is very likely in the presence of preserved left ventricular ejection fraction and protect heart from myocardial infarction despite the total occlusion of RCA and LAD.



### Figure legends:

**Panel A-D:** Collateral circulation originating from chronic total occluded right coronary artery (RCA) is retrogradely filling chronic total occluded left-anterior descending artery (LAD) (**Panel A, black arrows and asterisk**), septal collaterals developed from retrogradely filled LAD, supplying blood flow to the distal part of chronic total occluded RCA (**Panel B, black arrows**), distal RCA filling by septal collaterals originated from retrogradely filled LAD again (**Panel C-D, black arrows**).

## References

1. Stoller M, Seiler C. Salient features of the coronary collateral circulation and its clinical relevance. *Swiss Med Wkly* 2015; 145:14154.
2. Koerselman J, van der Graaf Y, de Jaegere PP, Grobbee DE. Coronary collaterals: an important and underexposed aspect of coronary artery disease. *Circulation* 2003; 107:2507-11.

Received: 24/02/2015

Accepted: 11/09/2015

Published: 15/10/2015

### **Disclosure and conflicts of interest:**

Conflicts of interest were not reported.

### **Corresponding author:**

Dr. Umut Kocabaş

**Mail:** umutkocabas@hotmail.com

# Left ventricular myxoma

Ali Kutsal<sup>1</sup>, Murat Koç<sup>2</sup>

<sup>1)</sup> Dr.Sami Ulus Research and Training Hospital, Department of Cardiovascular Surgery, Prof. Dr., Ankara, Turkey

<sup>2)</sup> Dr.Sami Ulus Research and Training Hospital, Department of Cardiovascular Surgery, Op. Dr., Ankara, Turkey

## Abstract

A 31 year-old woman complaining of mild dyspnea and fatigue was admitted to our clinic. A two-dimensional echocardiogram revealed a 2x2 cm mobile mass in the left ventricle. A 2 x 3 cm mobile, pediculated, gelatinous mass originating from the left ventricular lateral wall was removed by left ventriculotomy and histological features of the tumor indicated a myxoma.

**Keywords:** Left ventricular myxoma, left ventricular mass, cardiac surgery

*Kutsal A, Koç M. Left ventricular myxoma. EJCM 2015; 03 (2): 27-30. Doi: 10.15511/ejcm.15.00227.*

## Introduction

Myxomas are round or oval tumors with a smooth or slightly lobulated surface. Most are polypoid, relatively compact, pedunculated, and mobile. Although intracardiac myxoma is the most common tumor of the heart with an estimated incidence of 0.5 per million population per year, only 3-4 % of myxoma occur in the left ventricle<sup>1,2,3</sup>.

Myxoma has the potential of producing a triad of obstruction, embolisation and constitutional symptoms. The symptoms have varied greatly, depending on the size and the localization of the tumor. Systemic manifestations, which are noted in 90 % of patients consist of weight loss, fever, anemia, elevated sedimentation rate and elevated immunoglobulin concentration (usually IgG). Surgery should be performed as soon as diagnosis is confirmed.

Left ventricular myxoma may be removed via the left atrium, left ventricle or transaortic approach. Tumor in the left ventricle outflow tract may be approached transaortically<sup>4</sup>, but this approach carries an increased risk for systemic embolization.<sup>5</sup> Left-sided transatrial exposure alone may be difficult to achieve without risking any damage to the subvalvar apparatus of the mitral valve. Ventriculotomy is another approach with possible damage to small coronary artery branches.<sup>5</sup>


Adequate surgical approach is important for preventing complications and recurrence.

## Case Report


A 31 year-old woman complaining of mild dyspnea and fatigue was admitted to our clinic. Physical examination were normal. A two-dimensional echocardiogram revealed a 2x2 cm mobile mass in the left ventricle. In addition to the routine blood tests, immunoglobulin concentrations, C3c and C4 levels were measured. IgG (14.220 g/l), IgM (1.244 g/l), IgA (1.209 g/l) and C4 levels (0.230 g/l) were normal. C3c level was higher than normal (1.169 g/l).

With the diagnosis of left ventricular mobile mass (myxoma ?) she was operated. After performing median sternotomy and systemic heparinization cardiopulmonary bypass with bicaval and aortic cannulation was initiated. After systemic cooling to 30°C, aortic cross clamp was applied and the heart was arrested with antegrade cold crystalloid cardioplegia. A left atriotomy was performed and the mitral leaflets were gently retracted. However, it was very difficult to reach the mass without damaging the subvalvular apparatus of the mitral valve. Therefore left ventriculotomy was performed.

A 2 x 3 cm mobile, pedunculated, gelatinous mass originating from the left ventricular lateral wall was re-



**Figure 1:** The appearance of the myxoma through the ventriculotomy.



**Figure 2:** A 2x3 cm, pedunculated gelatinous mass was resected.

moved. Then left ventriculotomy was closed with teflon strips. Histopathological examination confirmed the diagnosis of myxoma.

The postoperative course was uneventful, and the patient was discharged on the sixth postoperative day.

One year follow-up revealed no recurrence, and she was asymptomatic.

## Discussion

Intracardiac myxoma is the most common benign tumor of the heart which occurs most commonly in women from 30 to 60 years of age. Children have a higher incidence of ventricular myxoma than do adults.<sup>6</sup> Women are affected 3 times more often than are men and a short duration of symptoms is also characteristic. Emboli from left ventricular tumors may mimic multiple sclerosis.<sup>7</sup> Accurate preoperative information about a myxoma in relation to its shape, size, mobility, texture, number of lesions and the clear localization is indispensable for determining the most appropriate operative procedure.<sup>8</sup> Two dimensional echocardiogram or MRI are adequate diagnostic modalities for these information.

To minimize the risk of perioperative embolism, gentle handling of the heart during cannulation is important. Transaortic, transmitral or transventricular approach may be employed for left ventricular myxomas. Transventricular approach should be avoided when ever possible in order not to impair the left ventricular

function. The deepest localization of the myxoma in the left ventricle in our patient forces us to perform a ventriculotomy. We performed transmitral approach first, but as it was impossible to resect it without damaging the subvalvular tissue, we performed ventriculotomy. Both the myxoma and its pedicle were excised totally.

Following excision of the myxoma, the atrium and ventricle should be irrigated and aspirated carefully for any residual tumor fragments.<sup>9</sup>

It is concluded that excision of the cardiac myxoma is curative and radical tumor excision may prevent recurrence. The possible causes of recurrence are inadequate resection, tumor implantation during the operation, and multicentric growth.<sup>10</sup> At present, it is generally believed that the multigrowth potential of the tumor seems more important than inadequate surgical resection in determining recurrence. Even if benign, a recurrent myxoma may be clinically more aggressive than the primary tumor. The recommended approach during a secondary operation includes a thorough inspection of all cardiac chambers and complete excision of all growths, with a wider and deeper margin of underlying endocardium than usual. Regular follow up with serial two-dimensional echocardiograms is particularly important in this group, who are at a high risk for the development of additional metachronous cardiac lesions. Despite careful operation for recurrent myxoma, the risk of a second recurrence is high and has been estimated at 25 %.<sup>10</sup>

## References

1. Keeling IM, Oberwalder P, Anelli-Monti M, Schuchlenz H, Demel U, Tilz GP, Rehak P, Rigler B. Cardiac myxomas: 24 years of experience in 49 patients. *Eur J Cardiothorac Surg* 2002;22:971-977.
2. Cooley DA. Surgical treatment of cardiac neoplasms: 32-year experience. *Thorac Cardiovasc Surg* 1990;38(Suppl 2):176-182.
3. Reynen K. Cardiac myxomas. *N Engl J Med* 1995;333:1610-1617.
4. Natale E, Minardi G, Casali G, Pulignano G, Musumeci F. Left ventricular myxoma originating from the interventricular septum and obstructing the left ventricular outflow tract. *Europ J Echocardiography* 2008 ;9:84-85.
5. Keeling I, Oberwalder P, Rigler B. Transaortic Access for excision of a left ventricular myxoma. *Ann Thorac Surg* 1999;68:2383-2391.
6. Reddy SN, Sunil G, Kumar RK. Surgical removal of a left ventricular myxoma in an infant. *Ann Pediatr Cardiol.* 2013 ;6(2):179-81
7. Kawano H, Tayama K, Akasu K. Left ventricular myxoma: Report of a case. *Surg Today* 2000;30:1112-1114.
8. Schröder C, Leukhardt WH, Hsiao EM, Farah MG, Markowitz AH. Transaortic video-assisted resection of a recurrent left ventricular myxoma. *Ann Thorac Surg.* 2013 ;95(1):340-2.
9. Abad C, Novoa J, Delgado A, Alonso A. Myxoma of the Left Ventricle. *Tex Heart Inst J* 2014;41(4):395-400.
10. Qin W, Wang L, Chen X, Liu P, Wang R. Left ventricular myxoma: a case report. *J Biomed Res.* 2014 ;28(6):506-8.

Received: 14/03/2015

Accepted: 19/07/2015

Published: 15/10/2015

### Disclosure and conflicts of interest:

The authors declare no conflict of interest.

### Corresponding author:

Prof. Dr. Ali Kutsal

**Mail:** akutsal@gmail.com

# Alternative intervention for pericardial effusion article type: Case report

Mehmet Atay<sup>1</sup>, Onur Saydam<sup>2</sup>, Vedat Bakuy<sup>3</sup>, Alparslan Şahin<sup>4</sup>

<sup>1</sup> Bakırköy Dr Sadi Konuk Training and Research Hospital Cardiovascular Surgery Department, İstanbul.

<sup>2</sup> Karaman State Hospital Cardiovascular Surgery Department, Karaman.

<sup>3</sup> Bakırköy Dr Sadi Konuk Training and Research Hospital Cardiovascular Surgery Department, İstanbul.

<sup>4</sup> Bakırköy Dr Sadi Konuk Training and Research Hospital Cardiology Department, İstanbul

## Abstract

Pericardial effusion is defined as the increase in the fluid levels between pericardial sheets. It may occur as a result of many etiological factors. Cardiac tamponade is the most important complication of the Pericardial effusion. Therefore it requires close follow-up and primary treatment. There are many treatment approaches. It can be treated with pericardiocentesis needle and catheter, surgical pericardial window opening with subxiphoidal approach and left anterior thoracotomy, pericardiectomy with open thoracotomy and video thoracoscopic pericardiectomy assists (VATS) can also be applied. Nowadays especially for recurrent PE less invasive procedures are becoming more popular than open surgery. For this reason in this article, we mentioned about video assisted thoracoscopic surgery (VATS) method in a patient diagnosed with a recurrent pericardial effusion without any underlying etiologic factors. VATS method should be considered in elective cases which pericardiocentesis cannot be drained, effusion with fibrinous formation, treatment of posterior side effusions. VATS method is recommended especially in patients with pericardial effusion accompanied by pleural and lung disease.

**Keywords:** Pericardial Effusion, cardiac tamponade, video assisted thoracoscopic surgery.

Atay M., Saydam O., Bakuy V., Şahin A. Alternative intervention for pericardial effusion article type: Case report. EJCM 2015; 03 (2): 31-34. Doi: 10.15511/ejcm.15.00231.

## Introduction

Pericardial effusion (PE) is defined as the increase in the fluid levels between pericardial sheets. It may occur as a result of many etiological factors. Cardiac tamponade is the most important complication of the PE.<sup>(1)</sup> Therefore it requires close follow-up and primary treatment. Many medical conditions can cause PE such as viral and bacterial infections, cancer, trauma, myocardial infarction, renal failure, autoimmune disease and idiopathic.<sup>(1)</sup> There are many treatment approaches. It can be treated with pericardiocentesis needle and catheter, surgical pericardial window opening with subxiphoidal approach and left anterior thoracotomy, pericardiectomy with open thoracotomy and video thoracoscopic pericardiectomy assists (VATS) can also be applied.<sup>(2)</sup>

Nowadays especially for recurrent PE less invasive procedures are becoming more popular than open surgery. For this reason in this article, we mentioned about video assisted thoracoscopic surgery (VATS) method in a patient diagnosed with a recurrent pericardial effusion without any underlying etiological factors.

## Case

58 years old male with no known medical history was admitted to the cardiology clinic with shortness of breath and fatigue. His blood pressure was 90/55 mmHg and heart rate was 98 bpm. In his physical examination jugular venous distention was observed and hearth sound was unremarkable. An electrocardiogram showed low QRS voltage and abnormal P wave changes. X-ray showed cardiomegaly and pulmonary vascular congestion. Laboratory results show no evidence of any viral or bacterial infections. Cardiac enzymes were in normal range. Echocardiography was performed and showed severe PE, normal left ventricular ejection fraction of % 60 with normal left ventricular size and wall motion. Computerized tomography was performed to rule out etiological factors (**Figures 1**).

Therefore, needle pericardiocentesis performed under local anesthesia. 300 cc serous fluid was drained and sent to cytology. Two days after pericardiocentesis echocardiography showed decreased in pericardial


effusion and showed normal left ventricular ejection fraction. Patient was discharged from hospital without any symptoms. Approximately 1 month after on this event, effort chest pain developed in patient. Electrocardiography showed ST depression in V4-6 and elevation in aVR. Coronary angiography performed. Critical isolated left anterior descending coronary artery (LAD) stenosis monitored in patient and stent was mounted. 2 months after the LAD stent placement the patient was admitted to the clinic again with shortness of breath. Echocardiography was performed and advanced pericardial effusion determined but this time pericardial effusion could not drained with pericardiocentesis due to fibrin formation. Thereupon, the patient was consulted and was hospitalized with operation plan in our clinic.

Endoscopic ports on the right side of the chest were placed under general anesthesia. Severe adhesions in the right lung were observed. Pericardium was seen after elimination of adhesions. About 2 cm incision was made on the pericardium. Pericardial fluid was drained (**Figures 2**). Pericardial fluid and material was sent to pathology. Drain was placed and layer was closed in anatomical plan. Postoperative follow-up period was normal and the patient was discharged after 4 days with healing.

## Discussion

Pericardial effusion is defined as the increase in the amount of accumulation of fluid in the pericardi-

**Figure 1A – 1B.** Preoperative computerized tomography images for pericardial effusion.




um. Cardiac tamponade is the most vital complication of pericardial effusion. Close follow should be performed with echocardiography. It can be treated with pericardiocentesis needle and catheter, surgical pericardial window opening with subxiphoidal approach and left anterior thoracotomy, pericardiectomy with open thoracotomy and video thoracoscopic pericardiectomy assists (VATS) can also be applied. There is no ideal method for the treatment of pleural effusion. Ensuring full and permanent drainage expected from an ideal method. Also, pericardial effusion material with biochemical, cytological and histological can be sampled with ideal method.

Furthermore, the method with the lowest risk and least invasive intervention for the patient should be selected.<sup>(2, 3)</sup> VATS procedure is a minimally invasive method. In this method unlike thoracotomy, ribs are not separated from each other, nerves and blood vessels

are not damaged and the integrity of the chest cavity remains intact. Patients have less pain in the postoperative period. Studies shows patients undergo VATS method have better pulmonary function than the patients undergoing thoracotomy.<sup>(4, 5)</sup> Because VATS is performed under general anesthesia and due to the cost, the use of VATS is limited in patients requiring emergency intervention.

VATS method should be considered in elective cases which pericardiocentesis cannot be drained, effusion with fibrinous formation, treatment of posterior side effusions. VATS method is recommended especially in patients with pericardial effusion accompanied by pleural and lung disease.<sup>(6)</sup> VATS method provides good field vision, opportunities to get a sample of tissue and less postoperative pain. Because all of this result VATS treatment of pericardial effusion can be used safely and effectively.

**Figure 2A – 2B.** Peroperative images of surgical field for opening pericardial window



## References

1. Yüksel Dereli, Ramis Özdemir, Musa Ağrı, Nihan Kayalar, Kemalettin Hoşgör, Ali Suat Özdiş, Perikardiyal Efüzyon Tedavisinde Subksifoidal Tüp Drenajı, Selçuk Üniv Tıp Derg 2011;27(4):190-192
2. Gökhan Önem, Ahmet Baltalarlı, A. Vefa Özcan, Harun Evrengül, İbrahim Gökşin, Mustafa Saçar, Oya Rendeci, Fahri Adalı, Kardiyak tamponad tedavisinde subksifoid perikardiyal pencere ve perkütan kateter ile drenaj, Türk Göğüs Kalp Damar Cer Derg 2006;14(2):107-110
3. Oktay BURMA, Hakan KÖKSAL, K. Kaan ÖZSİN, Ali RAHMAN, Perikardiyal Efüzyonun Subksifoid Yaklaşım ile Tedavisi, Fırat Tıp Dergisi 2004;9(1): 6-10
4. İlğaz DOĞUSOY, Tamer OKAY, Mehmet YILDIRIM, Murat YAŞAR-OĞLU, Atilla KANCA, Ali MERT, Ergin EREN, \*Bülent TUTLUOĞLU, Videotorakoskopi 11 Vakanın Değerlendirilmesi, Türk Göğüs Kalp Damar Cerrahi Dergisi Ocak 1994, Cilt 2, Sayı 1, Sayfa(lar) 43-47
5. Mack MJ, Aronoff RJ, Acuff TE, Douthitt MB, Bowman RT, Ryan WH: Present role of thoracoscopy in the diagnosis and treatment of diseases of the chest. Ann Thorac Surg. 54:403-9,1992
6. Yüksel Dereli, Ramis Özdemir, Musa Ağrı, Nihan Kayalar, Kemalettin Hoşgör, Ali Suat Özdiş, Perikardiyal Efüzyon Tedavisinde Subksifoidal Tüp Drenajı, Selçuk Üniv Tıp Derg 2011;27(4):190-192
7. Landreneau RJ, Hazelrigg SR, Mack MJ, Dowling RD, Burke D, Gavallick J, et al. Postoperative pain-related morbidity: video-assisted thoracic surgery versus thoracotomy. Ann Thorac Surg 1993;56:1285-9.
8. İlğaz ulsoy ve ark, Perikard efüzyonlu hastaların tedavisinde VATS ve torakotominin karşılaştırılması, Türk Göğüs Kalp Damar Cerrahisi Derg Ekim 2011, Cilt 19, Sayı 4, Sayfa(lar) 607-612
9. Iwasaki M, Nishiumi N, Maitani F, Kaga K, Ogawa J, Inoue H. Thoracoscopic surgery for lung cancer using the two small skin incisional method. Two windows method. J Cardiovasc Surg (Torino) 1996;37:79-81.

Received: 18/04/2015

Accepted: 27/07/2015

Published: 15/10/2015

### Disclosure and conflicts of interest:

Conflicts of interest were not reported.

### Corresponding author:

Dr. Mehmet Atay

**Mail:** drataym@gmail.com

# Heart sarcoma and invasion of the mitral valve: Case report

Lakehal Redha, Aimer Farid, Bouharagua Rabeh, Cherif Samiha, Massikh Nadjet, Aziza Baya, Bendjaballah Soumaya, Boukharoucha Radouane, Brahami Abdelmallek

<sup>1)</sup> Department of heart surgery, EHS Erriadh, Constantine, Algeria

## Abstract

Primary cardiac sarcoma is a malignant and rare type of tumor that occurs in the heart. About 25% of primary cardiac tumors are malignant, and 95% of these are sarcomas. The most common cardiac sarcoma is the angiosarcoma (about 37%), while others include undifferentiated sarcoma (24%), malignant fibrous histiocytoma (MFH) (11%–24%), leiomyosarcoma (8%–9%), and osteosarcoma (3%–9%). The diagnosis of these tumors is made by imaging techniques and pathological study. This new case report is an opportunity for us to make a reminder of this little-known entity among cardiologists and heart surgeon.

**Keywords:** Cardiac sarcoma, mitral valve, malignant fibrous histiocytoma.

*Redha L., Farid A., Rabeh B., et al. Heart sarcoma and invasion of the mitral valve: Case report. EJCM 2015; 03 (2): 35-39. DOI: 10.15511/ejcm.15.00235.*

## Introduction

Primary cardiac sarcoma is a malignant and rare type of tumor that occurs in the heart. About 25% of primary cardiac tumors are malignant, and 95% of these are sarcomas. The most common cardiac sarcoma is the angiosarcoma (about 37%), while others include undifferentiated sarcoma (24%), malignant fibrous histiocytoma (MFH) (11%–24%), leiomyosarcoma (8%–9%), and osteosarcoma (3%–9%). Less encountered primary tumors of the heart include rhabdomyosarcoma, liposarcoma, fibrosarcoma, synovial sarcoma, and heman-giopericytoma, with the least reported cardiac tumors being the intimal (spindle cell) sarcomas.

The mean age of presentation is around 40 years with no sex predilection. Patients present after variable periods of symptoms which are often non-specific, ranging from few weeks to several months and almost

all are symptomatic at presentation. The diagnosis of these tumors is made by imaging techniques and pathological study.

## Objective

This new case report is an opportunity for us to make a reminder of this little-known entity among cardiologists and heart surgeon.

## Methods

We report the case of 39 years old female presented with 2 months history of acute onset dyspnea, lethargy, weight loss, night sweats, and malaise. Clinical examination, blood tests and chest x ray were unremarkable.

**Chest X ray:**

**Echocardiography: Showed:**



Figure 1. Chest X ray




Figure 2. Echocardiography showing a tumor in the posterior wall of left atrium



Figure 3. Echocardiography showing a tumor in the posterior wall of left atrium



Figure 4. Echocardiography showing a tumor in the posterior wall of left atrium

A large (3, 8 × 2, 4 cm in diameter) echogenic and multi lobular mass in the left atrium with moderate mitral regurgitation. It is observed that the mass has invaded the left atrial wall and mitral valve.

**Transesophageal echocardiogram (TEE) and computed tomographic (CT) scan:** Don't realize.

### **Surgery**


She was referred for surgical assessment after the findings of left atrial mass. The patient was opened under cardiopulmonary bypass. The approach was sternotomy.

**The per operative exploration:** Infiltrating the left atrial wall and mitral valve. A curative resection was


deemed impossible. At surgery a large tumor was found arising from the left atrial side. It was solid in consistency and had a wide base. It was partly extending to mitral valve.

**The guesture** was resected of tumor as completely as possible and mitral valve replacement under CPB.


**Macroscopic examination of the cardiac specimen** revealed polypoid atrial masses weighing 30.4 grams with a side to side dimension of 4.3cm, length of up to 4.5cm, and a thickness of up to 2.9cm from the atrial endocardium. The mass involved the atrial wall posteriorly and the entire posterior mitral leaflet, except for its free margin. The most protuberant part of the mass was




**Figure 5.** Echocardiography showing a tumor in the posterior wall of left atrium



**Figure 6.** Operative view showing a heart tumor



**Figure 7.** Operative view showing a heart tumor



**Figure 8.** Operative view showing a heart tumor

considerably softer in consistency and deeper yellow in color with small darker areas.

## Results

**Duration of CPB:** 123mn.

**Aortic clamping:** 108mn.

**The immediate postoperative course** was simple.

**Stay in intensive care unit:** 48 hours.

**Intubation procedure:** 14hours.

**Post operative stay:** 07days.

**Histopathologic examination** of the left atrial mass showed an heart sarcoma. She underwent chemotherapy.

## Comments

Sarcomas of the left atrium are extremely rare primary cardiac tumors. Histologically, heart sarcomas are usually poorly differentiated mesenchymal malignant tumors of fibroblastic or myofibroblastic differentiation, consisting of atypical spindle cells with variable degrees of atypia, mitotic activity, necrosis, and nuclear polymorphism. The tumor may exhibit large myxoid areas and or epithelioid appearance of tumor cells. Tumor cells may resemble leiomyosarcoma and rarely exhibit


areas of rhabdomyomatous, angiosarcomatous.

The prognosis of cardiac primary sarcomas is generally poor. These tumors are highly aggressive with the mean survival being 3 months to 1 year. Cardiac tumors can cause significant morbidity and mortality. The effects of a cardiac tumor depend on its anatomical location in the heart, size, invasiveness, friability, and the rate of growth. The most important factor affecting the prognosis of these tumors is the anatomical location in the heart (intracavitary versus intra/extramycardial growth).

Although aggressive surgery can offer dramatic palliation of symptoms caused by valvular and/or vascular obstruction, local recurrence and metastasis occur frequently and early, usually within 1 year. Chemotherapy and radiation therapy have limited benefit.

## Conclusion

Heart surgery is the treatment of choice for sarcoma. Cardiac sarcomas generally lead to death within 2 years of diagnosis, due to rapid infiltration of the myocardium of the heart and obstruction of the normal flow of blood within the heart.



**Figure 9.** Operative view showing a heart tumor



**Figure 9.** Operative view showing a heart tumor after resection

## References

1. Straus R, Merliss R: Primary tumours of heart. Arch Pathol 1945, 39:74.
2. Reardon , Smythe : Cardiac neoplasms. In Cardiac surgery in the adult. 2nd edition. Edited by: Edmunds LH Jr. New york, NY:McGrawHill; 2003:1373–1400.
3. Mc Allister HA, Fenoglio JJ: Tumours of cardiovascular system in: Atlas of tumour pathology, series 2. Washington, DC: Armed Forces Institute of Pathology; 1978.
4. J. Butany, V. Nair, A. Naseemuddin, G. M. Nair, C. Catton, and T. Yau, “Cardiac tumours: diagnosis and management,” The Lancet Oncology, vol. 6, no. 4, pp. 219–228, 2005.
5. K. A. Ekmektzoglou, G. F. Samelis, and T. Xanthos, “Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations,” Journal of Cardiovascular Medicine, vol. 9, no. 8, pp. 769–777, 2008.
6. K. Reynen, “Frequency of primary tumors of the heart,” American Journal of Cardiology, vol. 77, no. 1, p. 107, 1996.
7. Z. Li, T. Hsieh, and A. Salehi, “Recurrent cardiac intimal (Spindle cell) sarcoma of the left atrium,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 27, no. 1, pp. 103–107, 2013.
8. G. J. Cho, H. J. Kim, and J. S. Kang, “Primary cardiac sarcoma in pregnancy: a case report,” Journal of Korean Medical Science, vol. 21, no. 5, pp. 940–943, 2006.
9. A. Modi, A. Lipnevicius, N. Moorjani, and M. Haw, “Prolonged survival with left atrial spindle cell sarcoma,” Interactive Cardiovascular and Thoracic Surgery, vol. 8, no. 6, pp. 703–704, 2009.
10. M. J. Perchinsky, S. V. Lichtenstein, and G. F. Tyers, “Primary cardiac tumors: forty years’ experience with 71 patients,” Cancer, vol. 79, no. 9, pp. 1809–1815, 1997.
11. H. P. Goldberg, F. Glenn, C. T. Dotter, and I. Steinberg, “Myxoma of the left atrium; diagnosis made during life with operative and post-mortem findings,” Circulation, vol. 6, no. 5, pp. 762–767, 1952.
12. W. R. Chitwood Jr., “Clarence Crafoord and the first successful resection of a cardiac myxoma,” Annals of Thoracic Surgery, vol. 54, no. 5, pp. 997–998, 1992.
13. B. Bode-Lesniewska, J. Zhao, E. J. M. Speel et al., “Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery,” Virchows Archiv, vol. 438, no. 1, pp. 57–65, 2001.
14. A. Gaumann, D. S. Tews, E. Mayer et al., “Expression of apoptosis-related proteins, p53, and DNA fragmentation in sarcomas of the pulmonary artery,” Cancer, vol. 92, no. 5, pp. 1237–1244, 2001.
15. M. H. Seelig, P. J. Klingler, W. A. Oldenburg, and J. L. Blackshear, “Angiosarcoma of the aorta: report of a case and review of the literature,” Journal of Vascular Surgery, vol. 28, no. 4, pp. 732–737, 1998.

Received: 17/03/2015

Accepted: 27/08/2015

Published: 15/10/2015

### Disclosure and conflicts of interest:

The authors declare no conflict of interest.

### Corresponding author:

Uz. Dr. Azam Jan

Mail: azamjan@hotmail.com

E-Journal of Cardiovascular Medicine welcomes scientific contributions in the field of cardiovascular and thoracic surgery - all aspects of surgery of the heart, vessels and the chest in various article types: new ideas, brief communications, work in progress, follow-up studies, original articles, best evidence topics, case reports, reports on unexpected results etc. All manuscripts shall be reviewed by the Editor-in-Chief, Associate Editors, Invited Referees and a Statistician when appropriate. If accepted, articles will be posted online and opened up for discussion. Acceptance criteria are based on the originality, significance, and validity of the material presented.

All material to be considered for publication in E-Journal of Cardiovascular Medicine should be submitted in electronic form via the journal's online submission system. (<http://my.ejmanager.com/ejcm/>)

A cover letter should be enclosed to all new manuscripts (to be filled in online), specifying the name of the journal and the type of paper, and including the following statements:

- The manuscript should not be previously published in print or electronic form and is not under consideration by another publication.
- All authors should contribute to the content of the article.
- All authors should read and approve the submission of the manuscript to ICVTS.
- Subject to acceptance, authors will sign an exclusive license to publish.
- No ethical problem or conflict of interest should exist.

If your first language is not English, we recommend that you consult an English language editing service to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication.

Manuscripts should be prepared using a word-processing package (save in .doc, .docx or .rtf format). The font type and font size should preferably be Arial or Times New Roman 11 points. The manuscript should be double-spaced and should include line and page numbers. The lines of the reference list do not need to be numbered; include a section break before.

#### Manuscripts should be organized as follows:

(a) Title page; (b) Abstract and Key words; (c) Text with the following sections (not applicable for article types with unstructured abstracts): Introduction, Materials and Methods, Results, Discussion, Acknowledgement (optional), Funding statement, Conflict of interest statement, (d) Figure (and Video) legends; (e) Tables; (f) References.

**Title page (1st page):** Title: should be brief and descriptive (100 characters) - no abbreviations are allowed, even if well known.

**Authors:** list all authors by full first name, initial of or full middle name and family name. Qualifications are not required. Ensure the author names correspond (in spelling and order of appearance) with the metadata of the system

**Institution(s):** include the name of all institutions with the location

(department, institution, city, country) to which the work should be attributed (in English). Use superscript numbers to connect authors and their department or institution.

**Corresponding author:** The full name, full postal address, telephone/fax numbers and the e-mail address should be typed at the bottom of the title page.

**Meeting presentation:** If the manuscript was (or will be) presented at a meeting, include the meeting name, venue, and the date on which it was (or will be) read; also indicate if you have submitted an Abstract of this manuscript for the EACTS or ESTS annual meeting and whether it has been accepted (if known).

**Word count:** The total number of words of the whole article (including title page, abstract, main text, legends, tables and references) must be specified on the title page.

**Abstract (2nd page):** An abstract should be a concise summary of the manuscript. Reference citations are not allowed. The abstract should be factual and free of abbreviations, except for SI units of measurement.

**Keywords:** Following the abstract, 3-6 keywords should be given for subject indexing.

**Introduction:** Should state the purpose of the investigation and give a short review of pertinent literature.

**Materials and methods:** Should be described in detail with appropriate information about patients or experimental animals. Use of abbreviations renders the text difficult to read; abbreviations should be limited to SI units of measurement and to those most commonly used, e.g. VSD, ASD, CABG (abbreviations should not be included in headings and extensions should be included at first mention).

**Results:** Results should be reported concisely and regarded as an important part of the manuscript. They should be presented either in tables and figures, and briefly commented on in the text, or in the text alone. Repetition of results should be avoided!

**Discussion:** The discussion is an interpretation of the results and their significance with reference to pertinent work by other authors. It should be clear and concise.

**Acknowledgement:** Acknowledgements and details of non-financial support must be included at the end of the text before the references. Personal acknowledgements should precede those of institutions or agencies.

**Tables:** All tables must be included in the manuscript file, should start on separate pages and be accompanied by a title, and footnotes where necessary. The tables should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in parentheses at the top of each column and not repeated in each line of the table.

**References:** Authors are responsible for checking the accuracy of all references. If you use EndNote or Reference Manager to facilitate referencing citations (not required for submission), this journal's style is available for use. References should be numbered in order of appearance in the text (in Arabic numerals in parentheses) and must be listed numerically in the reference list. Journal titles and author initials should be properly abbreviated and punctuated.

## GENERAL RULES

Files should be prepared as a Word document using font size 12 Times New Roman characters, double-spaced and with 2.5 cm margins on each side, top and bottom. Only standard abbreviations should be used; other shortened phrases should be indicated in parentheses as used in the text. Generic or chemical names of drugs should be used instead of trade names.

## ETHICAL ISSUES

### Publishing responsibilities of authors and Ethics

The publication of an article in a peer-reviewed journal is an essential building block in the development of a coherent and respected network of knowledge. It is a direct reflection of the quality of work of the author and the institutions that support them. Peer-reviewed articles support and embody the scientific method. It is therefore important to agree upon standards of expected ethical behavior.

### Reporting standards

Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review and professional publication articles should also be accurate and objective, and editorial 'opinion' works should be identified as such.

### Hazards and human or animal subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) has approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

### Use of patient images or case details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to us on request. Particular care should be taken with obtaining consent where children are concerned (in particular where a child has special needs or learning disabilities), where an individual's head or face appears, or where reference is made to an individual's name or other personal details.

## Originality and plagiarism

The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of

others, that this has been appropriately cited or quoted. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.

## Data access and retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

## Multiple, redundant or concurrent publication

An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. In general, an author should not submit for consideration in another journal a previously published paper. Publication of some kinds of articles (e.g. clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication.

## Acknowledgement of sources

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in those services.

## Fundamental errors in published works

When an author discovers a significant error or inaccuracy in his/her own published work, it is the author's obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learns from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

## Authorship of the paper

Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant

contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

## Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts. Before the accepted manuscript is published in an online issue:

Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager by the corresponding author of the accepted manuscript, and must include:

The reason the name should be added or removed, or the author names rearranged

Written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed

Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure described above.

### Note that:

- Journal Managers will inform the Journal Editors of any such requests
- Publication of the accepted manuscript in an online issue is suspended until authorship has been agreed
- After the accepted manuscript has been published in an online issue:

Any requests to add, delete or rearrange author names in an article published in an online issue will follow the same policies as noted above and may result in a corrigendum.

## TYPES OF PAPERS

### Original Articles

Original articles should consist of sections titled as “Abstract, Introduction, Materials and Methods, Results, Discussion and Conclusion”. For information about the abstract, refer to ‘Manuscript Formatting’ section.

The Introduction section of the manuscript should clearly state the purpose of the manuscript and include a brief summary of the most relevant national and international literature stating the main purposes and research question of the study. Contradictory aspects of the research, if present, should be mentioned. The expected contribution of this study to family medicine and practice should be highlighted.

The Materials and Methods section should describe the study population and the study design, with adequate information on the

techniques, materials and methods used. The section should include information of the study type, population, sample, sample size and selection of the sample. Validity and reliability of scales and questionnaires used also should be referred to. A clear description of the statistical methods should also be given.

The Results section should include a detailed report on the findings of the study. All figures, tables and illustrations should be used in this section. Results should be presented either as text or figures and/or tables and not be replicated.

The Discussion section of the study should emphasize the importance of the results and compare them with the results of other authors with relevant citations from the most recent literature. Study limitations and strengths should be specified. Suggestions for further studies in this area should be added.

The Conclusion should include the main conclusions based on the results of the research, emphasize the contributions of the study to family practice and propose original suggestions. A brief revision of all the results and the discussion should be avoided.

Original articles excluding case reports and systematic reviews should not exceed 3000 words excluding the abstract, references and tables. Case reports should not exceed 1000 words excluding the abstract, references and tables. There are no restrictions for systematic reviews.

### Short Reports

Short Reports are accepted when the research topic, aim and results of the study are limited in scope and in cases that do not require writing a full original article. Short Reports can be described as a summarized version that have been prepared according to the structure of research articles. Publishing an article as a short report does not reflect a lower quality. The same rules as relevant to original articles apply to preparing a short report, but structured abstracts are not mandatory references and tables should not exceed 6 and 2 in number, respectively. Abstracts should not exceed 100 words and the text should be restricted to a maximum of 1000 words.

### Reviews

Reviews are evidence-based articles about a specific topic using relevant citations from the most recent literature with the authors’ conclusions on this subject. The author is expected to have conducted research on the subject and to have experience in order to discuss and analyze the subject. There is no obligation to follow a particular format and may contain subtitles depending on the subject. The text should not exceed 4000 words excluding the title, abstracts, references and tables. E Journal of Cardiovascular Medicine, only publishes review articles solicited by the editors.

### Letters to Editor and Comments

Letters to the editor or comments can be sent to provide commentary and analysis concerning an article published in the journal, to give information about ongoing research, to provide informa-

tion in cardiology and cardiovascular-vascular-endovascular surgery, cardio-metabolic and vascular sciences. Letters to the editor or comments may include an optional title, tables and references. These articles should not exceed 1000 words.

### What Would You Do?

These are brief articles discussing cases and situations encountered in cardiology and cardiovascular surgery with a biopsychosocial approach. If necessary, photographs (with permission from the patient/owner) may be added. Sections should consist of a title, case report, discussion, questions and answers. Brief comments can be sent to provide commentary on previous articles and case reports written by other authors. Comments should include the number of the journal the article was published in. The text should not exceed 1000 words.

### International Reprints

Translations of important documents, declarations and guidelines prepared by international organizations in the field of cardiology and cardiovascular surgery, may be published in the journal. Presubmission Inquiry to the Editorial Board of the Journal before submitting the article is recommended. It is the translator's responsibility to obtain permission from the owner of the original manuscript for publication and translation.

### News

These articles focus on advances and innovations in clinical topics relevant to cardiology and cardiovascular surgery. There is no obligation to follow a particular format. The text should be limited to 1000 words.

### Editorials

Editorials usually provide information about the editorial policy of E Journal of Cardiovascular Medicine, give commentary and feedback on articles published in the journal, draw attention to topics of current interest and give information related to and discuss the development of cardiology and cardiovascular surgery in the world. They are mainly written by the members of the Editorial Board. Editorials are limited to 2000 words with some exceptions and may include a title and references when necessary.

## MANUSCRIPT FORMATTING

Manuscripts should be designed in the following order:

*Title page*

*Abstract*

*Main text*

*References*

*Tables, figures and illustrations*

### Title Page

The title page of the manuscript should include: The title, first

and last names of each author. Complete affiliation and title for each author, with the name of department (s) and institution (s) to which the work should be attributed.

The corresponding author should be clearly identified with name, address, telephone- facsimile number and email address for correspondence about the manuscript. Authors should clearly indicate if the article has previously been presented at a congress or scientific meeting. The title should be concise and informative without abbreviations and not exceed 10 words.

### Abstract

Abstracts should be exact in English, with a minimum of 150 and maximum of 350 words. Abstracts of original research articles should be structured under subheadings as follows: objectives, methods, results and conclusion. A maximum of 3 key words should be added to English abstracts.

### Text

The text contains the rest of the manuscript. It is structured differently according to the type of manuscript (original research article, review, etc.). For example, original research articles should consist of aim and objectives, methods, results, discussion and conclusion.

### References

References should be cited in consecutive numerical order as first mentioned in the text and designated by the reference number in parentheses. If the number of authors for the reference is more than 6 authors, list the first three authors and add "et al".

Journal names should be abbreviated as used in Index Medicus. References should be cited in the Vancouver style. For detailed information please visit the relevant link

### Examples:

**For research articles follow the example below:**

– Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality. JAMA 1995; 274(2): 131–6.

For book chapters follow the example below:

– Rakel RE. The family physician. In: Rakel RE, editor. Textbook of family practice. 5th ed. Philadelphia: W.B. Saunders; 1995. p. 3-19.

**For web pages follow the example below:**

– Guidance for clinicians. An International Benchmarking Study. <http://www.who.int/topics/surgery/> accessed: 29/09/2002.

### Tables and Figures

Legends should take place on the top of the page for tables, and bottom of the page for figures and placed on separate pages. Explain all nonstandard abbreviations in footnotes.



**E Journal of Cardiovascular Medicine**  
is a global e-journal targeting articles on:

- clinical cardiology,
- interventional cardiology,
- arrhythmia,
- cardiovascular surgery,
- vascular & endovascular surgery,
- vascular biology